Intuitive Surgical, Inc. (NASDAQ:ISRG) CEO Gary S. Guthart Sells 18,151 Shares

Intuitive Surgical, Inc. (NASDAQ:ISRG) CEO Gary S. Guthart sold 18,151 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the sale, the chief executive officer now directly owns 24,219 shares in the company, valued at approximately $12,391,166.97. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Intuitive Surgical Stock Down 1.5 %

ISRG traded down $7.60 on Thursday, hitting $506.17. The company’s stock had a trading volume of 664,970 shares, compared to its average volume of 1,459,089. The company’s 50 day simple moving average is $489.74 and its 200-day simple moving average is $445.30. The firm has a market cap of $180.29 billion, a P/E ratio of 82.60, a price-to-earnings-growth ratio of 5.11 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $260.17 and a 12 month high of $523.34.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Raymond James boosted their target price on shares of Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. The Goldman Sachs Group set a $604.00 target price on shares of Intuitive Surgical in a research note on Friday, October 18th. Morgan Stanley boosted their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Piper Sandler reissued an “overweight” rating and issued a $538.00 price objective (up previously from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Finally, Barclays upped their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $513.74.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ISRG. Graypoint LLC lifted its stake in Intuitive Surgical by 7.5% in the 3rd quarter. Graypoint LLC now owns 2,496 shares of the medical equipment provider’s stock worth $1,226,000 after purchasing an additional 175 shares in the last quarter. Concurrent Investment Advisors LLC lifted its stake in Intuitive Surgical by 98.7% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 9,873 shares of the medical equipment provider’s stock worth $4,850,000 after purchasing an additional 4,905 shares in the last quarter. Catalina Capital Group LLC lifted its stake in Intuitive Surgical by 6.6% in the 3rd quarter. Catalina Capital Group LLC now owns 2,668 shares of the medical equipment provider’s stock worth $1,311,000 after purchasing an additional 166 shares in the last quarter. Avidian Wealth Enterprises LLC raised its position in shares of Intuitive Surgical by 7.0% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 656 shares of the medical equipment provider’s stock valued at $322,000 after buying an additional 43 shares in the last quarter. Finally, Falcon Wealth Planning raised its position in shares of Intuitive Surgical by 0.4% during the 3rd quarter. Falcon Wealth Planning now owns 5,693 shares of the medical equipment provider’s stock valued at $2,797,000 after buying an additional 23 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.